Latest Headlines

Latest Headlines

Earbuds: The wearable med device of the future? Apple, Intel think so

Several companies are developing wearable biosensors in the form of wristbands, but the co-founder of biosensing technology company Valencell says the ear is the best to place collect vital signs, and giants Intel and Apple have earbud ambitions as well.  

MGC Diagnostics completes Belgian M&A deal with an eye on globalization

Minnesota's MGC Diagnostics has completed its acquisition of a promising Belgian competitor, putting its plan for global expansion in place less than a month after the M&A deal was first announced.

Stentys ditches bare metal stent trial as customers move to drug-eluting versions

Stentys announced that it is discontinuing enrollment of its Apposition V trial for its bare metal stent and focusing its resources and money on its next-generation sirolimus-eluting stent featuring a new delivery catheter.

Capnia IPO to raise $20M to market neonatal hemolysis test

Capnia expects to launch its breath-based device that would make the determination of whether newborn jaundice is a health threat easier and faster. This could potentially cut down the need for infant hospital readmissions due to jaundice.

Amgen builds case for bigger Kyprolis market with impressive second-line data

Amgen put out the word Monday that adding Kyprolis to combo therapy with Celgene's Revlimid beat out the Revlimid combo alone in melanoma patients who had relapsed.

Biotechs find themselves in R&D spotlight as Ebola hits the headlines

A month ago, Tekmira shares took a deep dive after the FDA placed a clinical hold on its Ebola therapy, the RNAi therapy TKM-Ebola, citing concerns about cytokine release--a condition which can spur a fatal noninfectious fever in the worst cases. The Canadian biotech's shot up more than 12% on Monday morning on speculation that the FDA would put the treatment back on its fast track.

Pfizer and Roche join Icon's adaptive-trial alliance

Pfizer and Roche are the latest pharma heavyweights to join Icon's consortium of drugmakers working to flesh out new technology for adaptive clinical trials, allowing study sponsors to react to results in real time and maximize efficacy.

Amgen preps for swift FDA review as Kyprolis/Revlimid combo stymies myeloma

Amgen put out the word Monday morning that Kyprolis--provided in a combo package with Celgene's Revlimid--beat out Revlimid alone in a head-to-head Phase III study for multiple myeloma, hitting the primary endpoint and offering the Big Biotech a shot at expanding its franchise for the drug at a critical moment in the company's history.

Affiris clears Phase I with Parkinson's vaccine candidate

Austria-based vaccinemaker Affiris announced that its Parkinson's disease vaccine has met its primary endpoint in a small Phase I safety trial of patients receiving two different doses of the jab.

Researchers develop 'intelligent knife' to distinguish between healthy tissue and tumors in surgery

The technology going into the device, called Rapid Evaporative Ionization Mass Spectrometry, by the Waters Corporation, is a move that one of the developers hopes will give the project new momentum.